Acetylcholinesterase inhibitors have generally been demonstrated to give significant, albeit modest, benefits in improving cognitive function and reducing hallucination severity in DLB patients; these effects may be sustained and associate with increased survival [24–26]. This evidence concerns the gene ACHE and Lewy body dementia.